Research Article

Leukogram Profile and Clinical Status in *vivax* and *falciparum* Malaria Patients from Colombia

Alberto Tobón-Castaño, Esteban Mesa-Echeverry, and Andrés Felipe Miranda-Arboleda

Grupo Malaria, Facultad de Medicina, Universidad de Antioquia, Calle 70, No. 52-21, Medellín, Colombia

Correspondence should be addressed to Alberto Tobón-Castaño; alberto.tobon1@udea.edu.co

Received 30 June 2015; Revised 4 October 2015; Accepted 20 October 2015

Academic Editor: Ib C. Bygbjerg

Copyright © 2015 Alberto Tobón-Castaño et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction. Hematological alterations are frequent in malaria patients; the relationship between alterations in white blood cell counts and clinical status in malaria is not well understood. In Colombia, with low endemicity and unstable transmission for malaria, with malaria *vivax* predominance, the hematologic profile in malaria patients is not well characterized. The aim of this study was to characterize the leukogram in malaria patients and to analyze its alterations in relation to the clinical status.

Methods. 888 leukogram profiles of malaria patients from different Colombian regions were studied: 556 with *P. falciparum* infection (62.6%), 313 with *P. vivax* infection (35.2%), and 19 with mixed infection by these species (2.1%).

Results. Leukocyte counts at diagnosis were within normal range in 79% of patients and 18% had leucopenia; the most frequent alteration was lymphopenia (54%) followed by monocytosis (11%); the differential granulocyte count in 298 patients revealed eosinophilia (15%) and high basophil counts (8%). Leukocytosis, eosinopenia, and neutrophilia were associated with clinical complications. The utility of changes in leukocyte counts as markers of severity should be explored in depth. A better understanding of these hematological parameters will allow their use in prompt diagnosis of malaria complications and monitoring treatment response.

1. Introduction

Malaria, a disease caused by protozoan parasites of the genus *Plasmodium*, is still considered a serious global public health problem [1]. There were approximately 198 million cases and 584,000 deaths in 2013, according to the World Health Organization (WHO) [2]; however it has been noted in recent years that there is significant underreporting of cases and deaths worldwide [3]. Fatal cases are mainly attributed to *Plasmodium falciparum*; however other plasmodia, like *P. vivax*, can cause serious illness and even death [4, 5].

Malaria can affect any organ or system, the hematological system being the most affected one. The majority of described alterations occur on the red cell line and platelets, causing anemia and thrombocytopenia [6–8]. Alterations in the white blood cell (WBC) counts are less reported and have been associated with factors such as severity, *Plasmodium* species, concurrent infections, and treatment response [9–12]. Descriptions of leukocytosis, leukopenia, neutrophilia, and neutropenia, presence of immature neutrophils, and changes in lymphocytes, monocytes, and eosinophils in these patients have been observed [13, 14], but studies have not shown a specific leukocyte profile alteration in malaria.

It has been found that WBC counts are generally lower in malaria patients compared to healthy patients and that there is a trend towards lower WBC counts in patients infected with either *P. falciparum* or *P. vivax* [15]. Additionally it has been observed that these changes are dynamic during illness, with lower lymphocyte and eosinophil counts at baseline and higher counts as the symptoms disappear [15, 16]. There have been descriptions of mortality-associated leukocytosis, presence of coinfections, and gram negative bacteremia in complicated cases of *P. falciparum* malaria [17].

Several theories attempt to explain these described hematological disorders, including (i) bone marrow (BM) suppression secondary to immune response imbalances, (ii) lower average cell life, and (iii) leukocyte redistribution to lymphoid organs and tissues with increased inflammatory response or sequestration in microvasculature [11, 14, 18–20]. However, these findings remain poorly understood and their utility in
clinical practice has not yet been established, unlike for other infectious diseases prevalent in tropical areas, such as Dengue [21].

The Complete Blood Count (CBC) assesses the cellular elements of the blood, that is, red cells, white cells, and platelets, both qualitatively and quantitatively [22] and is an essential tool in assessing hematological changes. The leukogram is part of the CBC that analyzes white blood cells; it comprises the total WBC and subpopulation counts including neutrophils, eosinophils, basophils, lymphocytes, and monocytes. Their reference values vary according to age, race, physiological condition (pregnancy), use of some drugs, and time of day [23]. The aim of this study is to characterize changes in the WBC count of patients with malaria from endemic regions in Colombia and to analyze variations according to clinical status, species of *Plasmodium*, and some sociodemographic characteristics of the patients. Our purpose is to encourage the use of easily accessible diagnostic tools, such as the CBC, allowing early identification of patients at risk for clinical complications and to implement appropriate therapeutic measures, improving patient outcome.

### 2. Methods and Materials

A descriptive retrospective analysis was made with clinical, laboratory, and demographic data from outpatients with *P. falciparum* or *P. vivax* malaria, from endemic regions in Colombia. The reference population consisted of patients of all ages with symptoms suggestive of malaria, with parasitological diagnosis confirmed with thick blood smear examination in first or second level of care hospitals and health care facilities in the municipalities of Turbo and Necocli (Urabá, Antioquia), El Bagre (Bajo Cauca, Antioquia), Tumaco, Guapi, and Timbiquí (Pacific Coast), and who were enrolled in clinical and epidemiological studies conducted by the Malaria Group between 1997 and 2007 [24–26]. We also included Medellín third-level hospitals’ inpatients’ data from 2005 to 2010, referred from different regions. Convenience sampling was performed for this analysis; only patients with a CBC performed at hospital admission were included, obtaining a sample of 888 patients.

The thick smear examination was done according to WHO recommendations [27]. After a medical assessment, a sample of blood was taken in EDTA for cellular and biochemical studies, including a CBC within 2 hours, obtained in 3rd- and 4th-generation automated analyzers (Abbott Diagnostics Cell-Dyn3200; Beckman Coulter, Coulter HmX; and Nihon Kohden Celltac MEK, Sysmex KX-21N). Colombian population reference values for the WBC counts were applied (Table 1) [28].

The WBC count, hemoglobin values, and platelets counts were qualitatively classified as low or high if they were above or below the normal range. Complications were classified according to WHO major criteria for severity [29] and to proposed minor criteria for Colombia [26] as follows:

1. Liver failure: severe liver failure (total bilirubin >3 mg/dL; AST >120 IU/L) or mild liver failure (total bilirubin >1.5–3 mg/dL; AST > 80–120 IU/L); (2) thrombocytopenia: profound (<25,000 platelets/µL) or severe (25–50,000 platelets/µL); (3) renal impairment: severe (BUN > 60 mg/dL or creatinine > 3 mg/dL) or mild (BUN 41–60 mg/dL or creatinine 1.5–3 mg/dL); (4) anemia: severe (hemoglobin < 5 gr/dL) or moderate (hemoglobin 5–6.9 gr/dL); (5) neurologic complication: cerebral malaria (seizures/coma) or extreme weakness; (6) pulmonary injury: acute respiratory distress syndrome (ARDS)/pulmonary edema or pleural effusion; (7) acid-base disturbance: severe acidosis (pH < 7.35 and HCO₃ < 15 mEq/L) or acidosis (pH < 7.35 and HCO₃ 15–18 mEq/L); and (8) hypoglycemia: severe (<40 mg/dL) or moderate (40–49 mg/dL).

Patients were divided into five age groups for analysis. Parasitemia was classified by ranges of parasites/µL in up to 1,000; 1,001–5,000; 5,001–10,000; 10,001–50,000; 50,001–100,000; and greater than 100,000.

#### 2.1. Statistical Analysis

The Kolmogorov-Smirnov test was used to assess normality for quantitative variables; the median values were compared with Mann-Whitney *U* test when variables were not normal. Associations between qualitative variables were analyzed with the χ² test. Spearman’s rank correlation coefficient was applied to analyze some relationships between numerical data. The adopted level of statistical significance was 5% (*P* < 0.05). The analysis was done with IBM SPSS statistics program, 22nd version (licensed to Universidad de Antioquia).

#### 2.2. Ethical Aspects

The patients studied prospectively were included after giving informed consent, endorsed by the Ethics Committee of the Medical Research Institute from the Medical School of the Universidad de Antioquia (Minute 31, July 2002; Minute 5, June 2005). The review of retrospectively studied patients’ medical records was approved by the Hospital Ethics Committees from Hospital Pablo Tobón Uribe and Hospital San Vicente Fundación (Letter 5282, October 2009).

### 3. Results

Blood counts of 888 patients were analyzed. The quantitative variables showed normal distribution, except hemoglobin (KS, *P* = 0.082). The sample consisted mostly of men (62.8%) over 15 years of age, with a mean age of 26 years (median 22.8). Age ranged from 1 month to 82 years. The geographic origin of the patients is shown in Figure 1. Some demographic characteristics are described in Table 2.

The time of disease progression to first medical consultation was known for 618 patients: 30% (*n* = 185) consulted within the first three days of onset of symptoms, 44.9% (*n* = 277) between days 4 and 7, and 21.3% (*n* = 132) from day 8 to 15; 38.8% of the study population consulted 2 weeks after the onset of symptoms. Previous use of antimicrobials was established (not antimalarial) in 39 (4.4%) patients (particularly penicillins in 23 and cephalosporins in 7) and antimalarials in 79 (8.9%) (particularly chloroquine and primaquine in 68 and quinine in 8). Complicated malaria was diagnosed in 257 patients (29%): 110 (12%) with major criteria and 147 (16.6%) with minor criteria for severity; no deaths were reported.
Mononuclear Cells. Lymphopenia prevailed in 54% (n = 476); the median value for these cells was 1,575/µL. Monocyte count was normal in 85% of cases (n = 749); the median count was 371 cells/µL.

Granulocytes (PMN). Some of the analyzed blood counts did not have differential granulocyte subpopulations counts and only had a total granulocyte count. Normal values were found in 91% of patients (n = 805). One-third of differential counts came from severe patients and the rest from nonsevere ones (66%).

3.2. Parasitemia and Plasmodium Species. There was a negative relationship between the number of parasites and the eosinophil count (Spearman coefficient –0.2; P = 0.010); no linear correlation was found with other cell populations. No differences in leukocyte subpopulations medians in relation to plasmodial species (P > 0.05) (Table 3).

3.2.3. Severe Malaria. Neutrophilia and eosinopenia were the most common alterations in severe malaria cases. The comparison between severe malaria (overall complications, diagnosed with major or minor criteria) and nonsevere malaria shows that leukopenia and leukocytosis, lymphopenia, eosinopenia, monocytosis, and neutrophilia were linked to severity (Table 5). These associations remained when only major criteria were applied, except for leukocytosis. When only minor criteria were applied, leukopenia (OR = 1.7; 1.1–2.6; P = 0.022), leukocytosis (OR = 2.5; 1.0–5.2; P = 0.039), lymphopenia (OR = 2.2; 1.5–3.2; P < 0.001), and eosinopenia (OR = 10.8; 2.1–55.6; P = 0.002) were associated with severity. Leucocyte counts are compared in relation to clinical condition in Table 6.

3.2.4. Glycemia and Leukocytes. Glycemia values were obtained from 357 subjects, averaging 107.6 mg/dL (37–264) with a median of 102 mg/dL. When glycemia was compared with leukocyte counts, patients with leucopenia had normal values in 91% of cases (n = 407); the median value was 3,836 cells/µL. Only 250 patients had eosinophil counts of which 80% (n = 201) were normal and 15% (n = 37) had eosinophilia; the median value for these cells was 176/µL. Eosinopenia was present in 5% (n = 12) of patients. Only 268 patients had basophil counts, of which 92% (n = 246) were within normal values. No patient in this group had counts below normal levels.

3.2.1. Age of Patients. The median neutrophil value was lower in children; there was greater variability in their counts with the highest individual neutrophil counts. Means and medians are presented in Table 3. No significant differences between groups were observed when values were assigned into the categories of normal, low, or high (P > 0.05). Children were more likely to have monocytosis (RR = 2.2, 1.4–3.5; P < 0.001), neutrophilia (RR = 2.3, 1.0–5.2; P = 0.046), and eosinophilia (RR = 2.2, 1.1–4.5; P = 0.029) than adults (Table 4).

3.1. Parasite Counts Description. P. falciparum infection was diagnosed in 556 patients (62.6%); P. vivax was in 313 (35.2%) and mixed infection by these species in 19 (2.1%). The median parasite count in 809 patients was 4,980/µL; 71.8% (n = 581) had counts lower than 10,000 parasites/µL and 1% (n = 8) had parasitemia above 100,000/µL. In parasitemia ranges, 19.9% had less than 1,000 parasites/µL, 51.8% between 1,000 and 10,000, 24.5% between 10,001 and 50,000, and 2.7% between 50,000 and 100,000.

Table 1: Leukogram reference values by age*.

| Age          | Leukocytes/µL | Neutrophils/µL | Lymphocytes/µL | Monocytes/µL | Eosinophils/µL | Basophils/µL |
|--------------|---------------|----------------|----------------|--------------|----------------|-------------|
| 1–15 days    | 9,000–30,000  | 1,000–12,000   | 3,000–9,000    | 30–750       | 40–500         | 0–50        |
| 16–31 days   | 5,000–21,000  | 1,000–12,000   | 3,000–9,000    | 30–750       | 40–500         | 0–50        |
| 1–12 months  | 6,000–17,500  | 1,000–12,000   | 3,000–9,000    | 30–750       | 40–500         | 0–50        |
| 1–5 years    | 5,500–15,500  | 1,700–7,500    | 3,000–9,000    | 30–750       | 40–500         | 0–50        |
| 6–14 years   | 4,500–14,500  | 1,500–6,500    | 2,000–7,200    | 30–750       | 40–500         | 0–50        |
| 15–99 years  | 4,500–11,000  | 1,500–8,000    | 1,500–4,000    | 30–900       | 40–500         | 0–50        |

*Leukogram counts based on gender not shown. Adapted from [28].

Table 2: Demographic characteristics of 888 malaria patients from Colombia.

| Characteristics | n | %  |
|-----------------|---|----|
| Gender          |   |    |
| Male            | 558| 63 |
| Female          | 330| 37 |
| Age             |   |    |
| Less than 1 year| 8 | 0.9|
| 1.1 to 5 years  | 50 | 5.6|
| 5.1 to 15 years | 193 | 21.7|
| 15.1 to 65 years| 624 | 70.3|
| Over 65 years   | 13 | 1.5|

### Table 1: Leukogram reference values by age.

| Age          | Leukocytes/µL | Neutrophils/µL | Lymphocytes/µL | Monocytes/µL | Eosinophils/µL | Basophils/µL |
|--------------|---------------|----------------|----------------|--------------|----------------|-------------|
| 1–15 days    | 9,000–30,000  | 1,000–12,000   | 3,000–9,000    | 30–750       | 40–500         | 0–50        |
| 16–31 days   | 5,000–21,000  | 1,000–12,000   | 3,000–9,000    | 30–750       | 40–500         | 0–50        |
| 1–12 months  | 6,000–17,500  | 1,000–12,000   | 3,000–9,000    | 30–750       | 40–500         | 0–50        |
| 1–5 years    | 5,500–15,500  | 1,700–7,500    | 3,000–9,000    | 30–750       | 40–500         | 0–50        |
| 6–14 years   | 4,500–14,500  | 1,500–6,500    | 2,000–7,200    | 30–750       | 40–500         | 0–50        |
| 15–99 years  | 4,500–11,000  | 1,500–8,000    | 1,500–4,000    | 30–900       | 40–500         | 0–50        |

*Leukogram counts based on gender not shown. Adapted from [28].
significantly higher blood glucose with a median of 108 mg/dL and those with normal WBC count had a median of 101 mg/dL ($P = 0.033$, Mann-Whitney); leukopenia patients had an increased risk of elevated blood sugar levels ($>140$ mg/dL) (OR = 2.6; 1.4–5; $P = 0.004$) compared with patients with a normal WBC count.

Lymphopenia patients had a median blood glucose of 109 mg/dL versus 95 mg/dL in patients with normal lymphocyte counts ($P < 0.001$, Mann-Whitney); lymphopenia was associated with an increased risk of high blood glucose levels ($>140$ mg/dL) (OR = 2.8; 1.3–5.7; $P = 0.007$).

Low granulocyte counts were related to lower blood glucose values, with a median of 81 mg/dL versus 103 mg/dL in patients with normal granulocyte counts ($P = 0.002$, Mann-Whitney), but the values remained within normal ranges. There was no higher risk of high blood glucose ($P < 0.05$) in patients with low granulocyte counts.
Table 3: Leukocyte subpopulations (cells/μL) by age ranges and malaria etiology.

|                  | Less than 1 year (n = 8) | 1.1 to 5 years (n = 50) | 5.1 to 15 years (n = 193) | 15.1 to 65 years (n = 624) | Over 65 years (n = 13) | P. falciparum** (n = 556) | P. vivax (313) |
|------------------|--------------------------|-------------------------|---------------------------|---------------------------|-----------------------|-------------------------|-----------------|
| **Leukocytes**   |                          |                         |                           |                           |                       |                         |                 |
| Mean             | 13,238                   | 8,360                   | 6,723                     | 6,438                     | 6,671                 | 6,597                   | 6,700           |
| CI*              | 6,592–19,883             | 7,480–9,240             | 6,289–7,158               | 6,250–6,627               | 5,676–7,667           | 6,385–6,810            | 6,414–7,086     |
| Median           | 10,050                   | 8,200                   | 6,200                     | 6,000                     | 6,000                 | 6,000                   | 6,200           |
| **Lymphocytes**  |                          |                         |                           |                           |                       |                         |                 |
| Mean             | 5,914                    | 3,803                   | 2,037                     | 1,639                     | 1,427                 | 1,897                   | 1,850           |
| CI               | 3,450–8,377              | 3,251–4,355             | 1,840–2,233               | 1,564–1,715               | 1,034–1,820           | 1,786–2,007            | 1,707–1,993     |
| Median           | 5,472                    | 3,473                   | 1,776                     | 1,451                     | 1,248                 | 1,585                   | 1,539           |
| **Monocytes**    |                          |                         |                           |                           |                       |                         |                 |
| Mean             | 776                      | 663                     | 462                       | 425                       | 436                   | 434                     | 454             |
| CI               | 193–1,360                | 479–846                 | 408–516                   | 398–452                   | 296                   | 402–466                 | 415–494         |
| Median           | 652                      | 434                     | 383                       | 348                       | 576                   | 360                     | 372             |
| **Granulocytes** |                          |                         |                           |                           |                       |                         |                 |
| Mean             | 6,516                    | 3,887                   | 4,188                     | 4,370                     | 4,829                 | 4,266                   | 4,420           |
| CI               | 1,422–11,610             | 324–453                 | 3880–4496                 | 4207–4532                 | 3,772–5,885           | 4,098–4,435            | 4,164–4,675     |
| Median           | 4,502                    | 3,590                   | 3,768                     | 4,128                     | 4,210                 | 3,950                   | 4,05            |
| **Neutrophils**  |                          |                         |                           |                           |                       |                         |                 |
| Mean             | 4,791                    | 3,753                   | 3,866                     | 4,264                     | 4,585                 | 4,087                   | 4,225           |
| CI               | 2,375–7,208              | 2,736–4,770             | 3,522–4,250               | 4,028–4,501               | 3,277–5,893           | 3,838–4,336            | 3,948–4,501     |
| Median           | 4,947                    | 3,432                   | 3,565                     | 3,950                     | 3,869                 | 3,780                   | 3,956           |
| **Eosinophils**  |                          |                         |                           |                           |                       |                         |                 |
| Mean             | 662                      | 413                     | 405                       | 292                       | 68                    | 279                     | 469             |
| CI               | 1,595–2,919              | 54–773                  | 203–606                   | 226–358                   | 33–101                | 228–330                 | 197–741         |
| Median           | 248                      | 224                     | 200                       | 179                       | 56                    | 168                     | 254             |
| **Basophils**    |                          |                         |                           |                           |                       |                         |                 |
| Mean             | 4                       | 54                      | 8                         | 15                        | 88                    | 12                      | 35              |
| CI               | 9–17                     | 8–117                   | 3–13                      | 2–28                      | 138–315               | 5–18                    | –6–77           |
| Median           | —                        | —                       | —                         | —                         | —                     | —                       | —               |

*CI: 95% confidence interval. **No differences found in WBC counts when comparing between species.
Table 4: White blood cells per μL in children and adults.

| Cell group            | Children               | Adults               |
|-----------------------|------------------------|----------------------|
| Leukocytes (medians)  | 6.650 (n = 252) (IR* = 3.675) | 6.000 (n = 636) (IR = 2.800) |
| Lymphocytes (medians) | 2.030 (n = 251) (IR = 1.835) | 1.442 (n = 634) (IR = 1.109) |
| Monocytes (medians)   | 400 (n = 251) (IR = 2.675)  | 348 (n = 435) (IR = 1.351)  |
| Neutrophils (medians) | 3.603 (n = 130) (IR = 2.154) | 3.927 (n = 316) (IR = 2.371) |
| Eosinophils (medians) | 204 (n = 79) (IR = 1.375)   | 168 (n = 171) (IR = 2.371)   |
| Basophils (mean value) | 34 (n = 87) (CI = 1.3–70)   | 23 (n = 179) (CI = 1.1–36)   |

* Interquartile ranges.
** 95% confidence interval.

Table 5: Comparison of leukocyte alterations between complicated and noncomplicated patients.

| Cell group | Normal n (%) | Low n (%) | High n (%) |
|------------|--------------|-----------|------------|
| Leukocytes |              |           |            |
| Complication (no) | 516 (73.9) | 96 (61.1) | 19 (57.6) |
| Complication (yes) | 182 (26.1) | 61 (38.9) | 14 (42.4) |
| OR (CI), P* | 1.8 (1.3–2.6), 0.001 | 2.1 (1.0–4.2), 0.038 |
| Lymphocytes |              |           |            |
| Complication (no) | 309 (79.0) | 309 (64.9) | 11 (61.1) |
| Complication (yes) | 82 (21.0) | 167 (35.1) | 7 (38.9) |
| OR (CI), P | 2.0 (1.5–2.8), 0.000 | 2.4 (0.9–6.4), 0.071 |
| Monocytes |              |           |            |
| Complication (no) | 543 (72.5) | 32 (74.4) | 54 (58.1) |
| Complication (yes) | 206 (27.5) | 11 (25.6) | 39 (41.9) |
| OR (CI), P | 0.9 (0.5–1.8), 0.783 | 1.9 (1.2–3.0), 0.003 |
| Neutrophils |              |           |            |
| Complication (no) | 278 (68.3) | 11 (73.3) | 10 (41.7) |
| Complication (yes) | 129 (31.7) | 4 (26.7) | 14 (58.3) |
| OR (CI), P | 0.8 (0.3–2.5), 0.680 | 3.0 (1.3–6.9), 0.007 |
| Eosinophils |              |           |            |
| Complication (no) | 133 (66.2) | 2 (16.7) | 29 (78.4) |
| Complication (yes) | 68 (33.8) | 10 (83.3) | 8 (21.6) |
| OR (CI), P | 9.8 (2.0–93.2), 0.001* | 0.5 (0.2–1.2), 0.143 |

* Odds ratio, confidence interval, and P value; ** Fisher’s exact test.

3.2.5. Leukocytes and Other CBC Variables. A direct correlation between the WBC and platelet counts (Spearman coefficient 0.27, P < 0.001) was found. This correlation is maintained with lymphocytes (0.27; P < 0.001), monocytes (0.14; P < 0.001), granulocytes (0.18; P < 0.001), neutrophils (0.12; P = 0.016), and eosinophils (0.25; P < 0.001). The median platelet count differed significantly between patients with leukopenia (100,000/μL; n = 154) and those without leukopenia (131,000/μL; n = 704) (P < 0.001, Mann-Whitney). Thrombocytopenia defined as a platelet count <150,000/μL was a risk factor for developing leukopenia, both with (OR = 5.8; 2.7–12.4) and without anemia (OR = 3.7; 0.9–7.4). Patients with severe thrombocytopenia had significantly lower leukocyte counts if infected with P. vivax (median 4,850 cells/μL) compared to P. falciparum infections (median 6,100 cells/μL) (P = 0.011, Mann-Whitney), a difference that was not observed by species of Plasmodium among patients without thrombocytopenia.

No correlation between leukocyte and erythrocyte counts was found (Spearman = 0.032; P = 0.364); the median erythrocyte count did not differ (P = 0.3133; Mann-Whitney) between patients with leukopenia (4,365,000/mm³; n = 142) and those without leukopenia (4,400,000/mm³; n = 620); hemoglobin values did not differ between patients with leukopenia (11.6 mg/dL; n = 157) and those without leukopenia (12.1 mg/dL; n = 698) (P = 0.164, Mann-Whitney). A negative correlation between lymphocyte and erythrocyte counts (Spearman = −0.18; P < 0.001) and a positive one between lymphocyte and neutrophils counts (Spearman = 0.18; P < 0.001) were found.

A negative relationship between the number of parasites and the eosinophil count was found (Spearman coefficient −0.18; P < 0.001); no linear correlation was found with other cell populations.

4. Discussion

Of the studied patients, 70% consulted after three days of febrile syndrome onset and 66% of the blood counts were performed between days 4 and 15 of the disease; thus WBC counts may reflect the response to repeated erythrocytic schizogony. One of the difficulties in establishing a pattern of leukocyte alteration during malaria episodes is the presence of different infection stages when the WBC count is analyzed. This variation in hematological parameters is expected as days pass from the onset of infection and may also be the
Table 6: Leucocyte counts (cells/μL) in relation to clinical condition*.

| Groups                     | Leukocytes | Lymphocytes | Monocytes | Neutrophils | Eosinophils |
|----------------------------|------------|-------------|-----------|-------------|-------------|
|                            | N Median   | P Median    | N Median  | P Median    | N Median    | P Median    |
| Complicated malaria        |            |             |           |             |             |             |
| Yes                        | 257 6,100  | 0.365       | 256 1,358 | 0.000       | 147 4,030   | 0.114       | 86 111     | 0.000       |
| No                         | 631 6,200  |             | 629 1,680 |             | 299 3,952   |             | 164 242    |             |
| Hepatic dysfunction        |            |             |           |             |             |             |             |             |
| Yes                        | 178 6,200  | 0.308       | 178 1,295 | 0.001       | 178 373    | 0.506       | 105 4,040  | 0.005       | 55 124     | 0.067       |
| No                         | 278 5,800  |             | 277 1,526 |             | 277 392    |             | 173 3,456  |             | 69 204     |             |
| Renal dysfunction          |            |             |           |             |             |             |             |             |
| Yes                        | 34 7,400   | 0.014       | 34 1,422  | 0.949       | 420 386    | 0.081       | 26 5,079   | 0.003       | 19 158     | 0.605       |
| No                         | 421 5,900  |             | 420 1,449 |             | 253 3,550  |             |             |             | 105 158    |             |
| Neurological complication  |            |             |           |             |             |             |             |             |
| Yes                        | 17 7,700   | 0.443       | 17 1,716  | 0.319       | 868 370    | 0.578       | 12 3,430   | 0.658       | 10 68      | 0.012       |
| No                         | 871 6,100  | 0.013       | 868 1,569 | 0.218       | 868 370    | 0.267       | 17 4,235   |             | 10 85      |             |
| Pulmonary complication     |            |             |           |             |             |             |             |             |
| Yes                        | 17 7,700   | 0.045       | 17 1,716  | 0.218       | 868 370    | 0.267       | 17 4,235   | 0.560       | 10 85      | 0.028       |
| No                         | 871 6,100  | 0.013       | 868 1,569 | 0.218       | 868 370    | 0.267       | 17 4,235   |             | 10 85      |             |
| Severe hypoglycemia (<49 gr/dL) | 4 8,300    | 0.318       | 4 807     | 0.246       | 4 191      | 0.209       | 2 8,009    | 0.004       | 1 N.D.     | 0.147       |
| Severe anemia              |            |             |           |             |             |             |             |             |
| Yes                        | 26 8,000   | 0.073       | 26 2,346  | 0.000       | 14 3,543   | 0.239       | 10 163     | 0.941       |             |             |
| No                         | 862 6,100  |             | 859 1,540 |             | 432 3,857  |             |             |             |             |             |
| Severe Thrombocytopenia    |            |             |           |             |             |             |             |             |
| Yes                        | 93 5,700   | 0.084       | 93 1,372  | 0.069       | 93 273     | 0.058       | 55 3,950   | 0.918       | 44 93      | 0.003       |
| No                         | 765 6,200  |             | 762 1,587 |             | 762 382    |             | 361 3,822  |             | 190 205    |             |
| Acidosis                   |            |             |           |             |             |             |             |             |
| Yes                        | 12 8,200   | 0.501       | 12 1,191  | 0.091       | 12 437     | 0.687       | 12 5,502   | 0.170       | 11 154     | 0.092       |
| No                         | 20 6,250   |             | 20 1,432  |             | 20 768     |             | 20 3,285   |             | 18 73      |             |

* Major or minor criteria for severe malaria.

The prevalent *Plasmodium* species in the cases studied was *P. falciparum*, in 63% of patients; this differs from the epidemiology of malaria in Colombia where the predominant species is *P. vivax*, a situation possibly due to the fact that more *falciparum* cases require hospitalization. Parasitemia ranges were below 10,000 parasites per microliter in 72% of patients (approximately less than 0.25% of parasitized erythrocytes). This variable was not associated with leukocyte alteration, except for the negative correlation between parasitemia and eosinophil counts (Spearman, *P* < 0.001).

The leukogram profile was similar in *P. vivax* and *P. falciparum* malaria. Although a strong inflammatory response in *P. vivax* infections has been recognized [30], our study did not find a differential leukocyte response by *Plasmodium* species, except for patients with severe thrombocytopenia and *P. vivax* infection, whose leukocyte counts were significantly lower, in accordance with previous findings in the acute phase of infection [31]. Leukopenia is a common finding in *falciparum* and *vivax* malaria [15, 16, 32]. Although some studies indicate that there is a greater trend towards leukopenia in infections with *P. falciparum*, this also happens with *P. vivax* [15, 33, 34]. Therefore the presence of leukopenia or its severity does not seem to be useful for diagnosis of species.

Although *Plasmodium* sp. is a hemoparasite, it has been observed that malaria does not significantly affect WBC counts, with values that are usually normal for total leukocyte population for both granulocyte and mononuclear cell sub-populations. Publications on leukocyte alterations in patients with malaria mostly reported WBC counts within normal ranges [9, 32–36]. These findings are consistent with our results where 85% of patients had normal leukocyte counts. The leukocyte, lymphocyte, monocyte, and neutrophil counts differed significantly between children and adults, but the values were within normal limits; therefore these differences appear to be due to physiological variability between groups.

Some changes have been reported in the distribution of WBC lines during the acute phase of malaria infection as well as the return to normal values during the convalescent phase [31], and there is a clear normalizing trend of WBC counts after disease resolution [15], meaning that WBC counts could be used as an indicator for the progress of disease, providing guidance for its management.
4.1. Leukopenia. Leukopenia is an alteration present in both *falciparum* and *vivax* malaria [15, 16]. Our study found that leukopenia was more frequent (18%) than leukocytosis (4%). This is the most reported alteration in malaria with frequencies up to 22% [13, 34, 36, 37]. Leukopenia (WBC < 6,100 cells/µL) was present in 10.2% [17] of Kenyan children over 3 months of age, hospitalized with *P. falciparum* malaria. Using a cutoff value of <4,000 cells/µL to define leukopenia, this alteration was observed in 22.1% of infections by *P. vivax* and 18.4% of mixed infections [37]. In experimental infections with *P. falciparum*, counts under 3,000 cells/µL were identified in 12% (n = 83) and counts under 1,000 cells/µL were in 9% (n = 79) [38]. In the UK leukopenia was described in 7% of patients with imported *P. falciparum* malaria [39].

Leukopenia in malaria can be caused by the interaction of various events. It has been proposed that the sequestration of leukocytes causes the decline in WBC counts more than a decreased production or accelerated destruction [11]. Glycosylphosphatidylinositol (GPI), an immunogenic antigen common to all species of *Plasmodium*, stimulates the production of proinflammatory cytokines in monocytes and macrophages [15, 40]; this would increase phagocytosis generating cell debris and increasing RBC and WBC phagocytosis, thus maintaining increased proinflammatory cytokine levels, particularly TNF-α, causing altered hemopoiesis [15, 41, 42].

4.2. Leukocytosis. Leukocytosis frequency in malaria varies from one study to another [11–13, 39] and is reported predominantly in *falciparum* malaria. This alteration was identified in 4% of our patients, without statistically significant differences by *Plasmodium* species (P > 0.05); the presence of coincidences that may explain leukocytosis was not studied. Leukocytosis occurs mainly by increased PMN numbers, but lymphocytosis, monocytosis, and eosinophilia can also occur [15, 17, 34]. A study of the cellular composition of BM [9] concluded that during *Plasmodium* infection there was a decrease in some core precursors and in PMN reserves, with increased circulation of immature PMN (bands) and abnormalities in their response to stimuli with drugs and endotoxin; the initial stimulus of infection on the BM reserves and increased circulating half-life of PMN lead to a transient leukocytosis. In *falciparum* malaria, leukocytosis has been explained by the stimulus of infection on the BM to release leukocytes during the paroxysms [16]; increased proinflammatory cytokines could favor the exit of leukocytes from BM [14] or by the presence of bacterial or viral coinfections [12], considering that these possible diagnoses were not excluded in some of the studies [17].

Comparative studies between severe and nonsevere malaria point out leukocytosis as a marker of severity and a predictor of death. A WBC count greater than 16,500 cells/µL was associated with a 7.14 times greater risk of death; mortality was related to the occurrence of bacteremia, polypnea, and coma [17]. When comparing severe and nonsevere patients, leukocytosis was found in 19% of severe and 12.7% of uncomplicated malaria patients; leukocytosis patients were younger and had other manifestations of severe malaria such as hypoglycemia and severe anemia and a 3.5 times greater risk of dying [12]. In our study 33 patients had leukocytosis and 42% of them had some complications (OR = 2.01; 1.1–4.2; P = 0.040); specifically renal dysfunction was related to this alteration.

4.3. Lymphocytes. Lymphopenia was the most common abnormality in our patients, present in 54% of cases, while only 2% had lymphocytosis; it was associated with thrombocytopenia as were leucopenia and neutropenia (P < 0.001). In the acute-stage malaria infection lymphopenia (defined as an absolute lymphocyte count ≤1500 cells/µL) was common in *vivax* and *falciparum* cases [15]. This finding was similarly reported in 63% of patients with imported *falciparum* malaria; and along with thrombocytopenia it represented the most common alteration [39]. The etiology of lymphopenia is open to discussion; it has been proposed that during the onset of infection lymphocyte counts drop due to lymphocyte stimulation through inflammation and their following distribution to more active tissues [43] followed by a reorganization of cellular distribution after disease resolution with a return to normal values [44]. A study in animal models found, however, significant elevations of serum apoptotic factors such as Fas and FasL in macaques, which were more susceptible to malaria complications and developed a more pronounced lymphopenia at the expense of T cells [45]; these findings were subsequently confirmed in humans with *P. falciparum* malaria: samples from these patients showed higher values of the aforementioned apoptotic factors at diagnosis and a progressive decrease as the treatment advanced, coinciding with an increase in lymphocyte counts [46]. Despite these results, a clear correlation between elevated Fas-FasL and decreased lymphocytes counts has not been established [47] and both are believed to be the result of malaria immune hyper-stimulation causing lymphocyte downregulation to maintain cellular homeostasis or a strategy of the *Plasmodium* genus parasites to decrease immune response [48]. Sequestration of lymphocytes in organs such as the spleen, presence of atypical or plasmacytoid lymphocytes, or decreased survival of these cells have been described [14, 15, 19].

Lymphopenia is a complex pathogenic phenomenon that may have important clinical effects in patients because of the transient immunodeficiency state that can occur and the increased risk of complications [44]; lymphopenia in our patients was associated, in general, with severity and specifically with moderate or severe hepatic dysfunction.

4.4. Monocytes and Granulocytes. Reported changes in other WBC like monocytes and eosinophils are less frequent; eosinopenia has been reported at malaria diagnosis [14–16], but, overall, there has been full recovery during the course of the disease, returning to normal values or even tending to mild eosinophilia at the end of treatment [16, 48]. In our patients 85% of monocyte and 91% of granulocyte counts were normal. Monocytosis presented in 11% of cases and it was associated with severe anemia, in line with the above findings for lymphocytosis. Although it has been described that PMNs are largely responsible for the elevation
of leukocyte counts, a strong association of monocytosis and lymphocytosis with mortality has been highlighted [17].

Eosinophilia was the most frequent alteration in granulocytes (15% of 250 patients) while eosinopenia was identified in 5% of cases, which was associated with severe malaria and specifically with neurological, pulmonary, and renal complications and with severe thrombocytopenia. Low eosinophil levels have been reported in the early stage of acute *falciparum* and *vivax* infections (normal values ≤350 cells/μL), with increasing levels over the following few weeks [15]. Increased eosinophil counts have been associated with better recovery from malaria anemia secondary to allergies caused by drugs [16] and have also been proposed as an indicator of adequate response to treatment in malaria patients [14, 15].

Neutrophil counts were normal in 91% of cases, with neutrophilia prevailing over neutropenia (5% versus 3%); it was associated with severe malaria and specifically with severe hypoglycemia and moderate or severe liver and kidney dysfunction. Altered basophil counts were not associated with severity. Although differential granulocyte counts were not available for all patients, 33% came from severe cases, which ensures inclusion of complicated and noncomplicated patients in the analysis.

4.5. Leukocytes, Erythrocytes, and Platelets. Leukocyte changes were not related to the decrease in erythrocyte counts and hemoglobin, except for the relation of monocytosis and lymphocytosis with severe anemia in 26 patients. It is possible that a larger number of cases of severe anemia allow identifying other abnormalities in the WBC count. Platelet count, by contrast, positively correlated with changes in all the white lines (Spearman correlation, \(P < 0.05\)) and total leukocyte lymphocyte, monocyte, and eosinophil counts were lower in patients with severe thrombocytopenia though only eosinophils showed statistical significance. These findings suggest an active role of leukocytes in platelet sequestration sites, via cellular aggregation, a phenomenon described for platelets [49] and leukocytes [50].

4.6. Leukocytes and Glycemia. A trend of increasing blood glucose was observed in patients with leucopenia and the frequency of hyperglycemia was higher, with statistical significance; specifically lymphopenia was associated with higher blood sugar levels. On the contrary, neutrophilia was associated with severe hypoglycemia, a complication occurring in only 4 patients.

5. Conclusions

Malaria hematological changes are diverse and can vary according to study, *Plasmodium* species, age, gender, and other factors. Although some studies have recognized the relationship between leukocytosis and clinical complications in malaria, the general picture involving the role of leukocytes that may play a key role is not entirely clear. The few studies that analyze the leukogram profile in malaria do not delve into the relationships of the leukocyte counts and the clinical condition of patients. This is one of the largest series of leukograms published in an attempt to explain the usefulness of this information as an indicator of severity.

The leukogram profile was similar in *P. vivax* and *P. falciparum* malaria. Leukocyte counts were within normal range in 79% of patients and 18% had leucopenia; the most frequent alteration was lymphopenia (54%) followed by monocytosis (11%). In this study, alterations in leukocyte counts were related to clinical complications according to major criteria of severity; specifically lymphopenia, eosinopenia, monocytosis, and neutrophilia were indicators of serious injury. Leukopenia, lymphopenia, and eosinopenia were related to complications in patients with minor criteria, probably indicating that leukocyte changes begin early and may suggest the onset of serious injury.

Despite the limitations related to retrospective analysis, this study contributes to a better compression about the leukocyte response to plasmodial infection and its relation with the clinical status. The blood samples were processed in 3rd- and 4th-generation automated analyzers; this reflects the technological level and the devices that are available in endemic regions, used to make treatment decisions. Taking into account the limitations of the information provided by these devices, our findings’ information could be used to recognize clinical deterioration and to provide adequate care and support.

This study determined changes in the WBC count of malaria patients and analyzed variations according to clinical status. Some alterations in the WBC profile were related to clinical severity and could allow early identification of patients at risk for medical complications. Their utility as markers of severity should be explored in depth, in addition to their application, to identify disease resolution. A better understanding of these hematological parameters will allow their use in early diagnosis of malaria complications and monitoring treatment response.

Conflict of Interests

The authors declare that they have no competing interests.

Authors’ Contribution

Alberto Tobón-Castaño and Andrés Felipe Miranda-Arboleda participated in the study design, data collection, data analysis, and writing of the paper. Esteban Mesa-Echeverry contributed to data analysis and writing of the paper.

Acknowledgments

The authors are thankful to “Grupo Malaria, Universidad de Antioquia,” “San Vicente de Paúl” and “Pablo Tobón Uribe” Hospitals, who provided data analyzed in this study, and to Ana del Mar Cortina, Ana Maria Cadavid, Lia Palacio, and Shirley Jolianiz, medical students at the School of Medicine of Universidad de Antioquia, for their support in seeking hospital medical records. This project was funded by Universidad de Antioquia, Colombia (Grupo Malaria de
References

[1] World Health Organization, Global Malaria Action Plan for a Malaria-Free World. Geneva, Switzerland: Roll Back Malaria Partnership, 2008, World Health Organization, 2008.

[2] WHO, World Malaria Report 2014, World Health Organization, 2014.

[3] The Lancet, “New estimates of malaria deaths: concern and opportunity,” The Lancet, vol. 379, no. 9814, p. 385, 2012.

[4] R. N. Price, N. M. Douglas, and N. M. Anstey, “New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance,” Current Opinion in Infectious Diseases, vol. 22, no. 5, pp. 430–435, 2009.

[5] S. Picot and A.-L. Bienvenu, “Plasmodium vivax infection: not so benign,” Medecine/Sciences, vol. 25, no. 6-7, pp. 622–626, 2009.

[6] M. V. G. Lacerda, M. P. G. Mourão, H. C. Coelho, and J. B. Santos, “Thrombocytopenia in malaria: who cares?” Memorias do Instituto Oswaldo Cruz, vol. 106, supplement 1, pp. 52–63, 2011.

[7] J. P. Quintero, A. M. Siqueira, A. Tobón et al., “Malaria-related anaemia: a Latin American perspective,” Memorias do Instituto Oswaldo Cruz, vol. 106, supplement 1, pp. 91–104, 2011.

[8] E. L. Martínez-Salazar and A. Tobón-Castaño, “Platelet profile is associated with clinical complications in patients with vivax and falciparum malaria in Colombia,” Revista da Sociedade Brasileira de Medicina Tropical, vol. 47, no. 3, pp. 341–349, 2014.

[9] D. C. Dale and S. M. Wolff, “Studies of the neutropenia of acute malaria,” Blood, vol. 41, no. 2, pp. 197–206, 1973.

[10] T. Händsch, M. Längin, B. Lell et al., “Full blood count and haemoglobin-containing leukocytes in children with malaria: diagnostic value and association with disease severity,” Malaria Journal, vol. 7, article 109, 2008.

[11] F. E. McKenzie, W. A. Prudhomme, A. J. Magill et al., “White blood cell counts and malaria,” Journal of Infectious Diseases, vol. 192, no. 2, pp. 322–330, 2005.

[12] D. Modiano, B. S. Sirima, A. Konaté, I. Sanou, and A. Sawadogo, “Leucocytosis in severe malaria,” Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 95, no. 2, pp. 175–176, 2001.

[13] W. R. J. Taylor, H. Widjaja, H. Basri et al., “Changes in the total leukocyte and platelet counts in Papuan and non Papuan adults from northeast Papua infected with acute Plasmodium vivax or uncomplicated Plasmodium falciparum malaria,” Malaria Journal, vol. 7, article 259, 2008.

[14] S. N. Wickramasinghe and S. H. Abdalla, “Blood and bone marrow changes in malaria,” Baillieres Best Practice and Research in Clinical Haematology, vol. 13, no. 2, pp. 277–299, 2000.

[15] N. Tangpukdee, H. S. Yew, S. Krudsood et al., “Dynamic changes in white blood cell counts in uncomplicated Plasmodium falciparum and P. vivax malaria,” Parasitology International, vol. 57, no. 4, pp. 490–494, 2008.

[16] B. González, H. Rodulfo, M. De Donato, M. Berrizbeitia, C. Gómez, and L. González, “Variaciones hematológicas en pacientes con malaria causada por Plasmodium vivax antes, durante y después del tratamiento,” Investigación Clínica, vol. 50, no. 2, pp. 187–201, 2009.

[17] S. Ladhani, B. Lowe, A. O. Cole, K. Kowuondo, and C. R. J. C. Newton, “Changes in white blood cells and platelets in children with falciparum malaria: relationship to disease outcome,” British Journal of Haematology, vol. 119, no. 3, pp. 839–847, 2002.

[18] Q. De Mast, F. C. G. J. Sweep, M. McCall et al., “A decrease of plasma macrophage migration inhibitory factor concentration is associated with lower numbers of circulating lymphocytes in experimental Plasmodium falciparum malaria,” Parasite Immunology, vol. 30, no. 3, pp. 133–138, 2008.

[19] H. Helmy, G. Jönsson, and M. Troye-Blomberg, “Cellular changes and apoptosis in the spleens and peripheral blood of mice infected with blood-stage Plasmodium chabaudi chabaudi AS,” Infection and Immunity, vol. 68, no. 3, pp. 1483–1490, 2000.

[20] K. Mohan and M. M. Stevenson, “Dyserythropoiesis and severe anaemia associated with malaria correlate with deficient interleukin-12 production,” British Journal of Haematology, vol. 103, no. 4, pp. 942–949, 1998.

[21] C. J. Gregory, O. D. Lorenzi, L. Colón et al., “Utility of the tourniquet test and the white blood cell count to differentiate dengue among acute febrile illnesses in the emergency room,” PLoS Neglected Tropical Diseases, vol. 5, no. 12, Article ID e1400, 2011.

[22] G. Campuzano, “Del hemograma manual al hemograma de cuarta generación,” Medicina & Laboratorio, vol. 13, pp. 511–550, 2007.

[23] G. Campuzano, Utilidad del Extendido de Sangre Periférica: Los Leucocitos, vol. 14, Medicina & Laboratorio, 2008.

[24] A. Tobón, C. Giraldo, J. G. Piñeros, M. Arboleda, S. Blair, and J. Carmona-Fonseca, “The epidemiology of complicated falciparum malaria: case and controls study in Tumaco and Turbo, Colombia, 2003,” Revista Brasileira de Epidemiologia, vol. 9, no. 3, pp. 283–296, 2006.

[25] S. Blair, G. Álvarez, and G. Campuzano, “Relación entre anemia y malaria en una población rural de Colombia,” Boletín de Malariología y Salud Ambiental (Venezuela), no. 37, pp. 7–13, 1997.

[26] A. Tobón-Castaño, C. Giraldo-Castro, and S. Blair, “Prognostic value of clinical and parasitological signs for severe malaria in patients from Colombia,” Biomédica, vol. 32, supplement 1, pp. 79–94, 2012.

[27] F. J. Lopez Antuñano and G. Schmunis, Diagnóstico de Malaria, Publicación Científica no. 512, OMS, Washington, DC, USA, 1988.

[28] G. Campuzano, “Interpretación del hemograma automatizado: claves para una mejor utilización de la prueba,” Medicina & Laboratorio, vol. 19, no. 1-2, pp. 61–68, 2013.

[29] WHO, “Severe falciparum malaria, World Health Organization, Communicable Diseases Cluster,” Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 94, supplement 1, pp. SI–S90, 2000.

[30] B. E. Barber, T. William, M. J. Grigg et al., “Parasite biomass-related inflammation, endothelial activation, microvascular dysfunction and disease severity in vivax malaria,” PLoS Pathogens, vol. II, no. 1, Article ID e1004558, 2015.

[31] R. N. Rodrigues-da-Silva, J. D. C. Lima-Junior, B. D. P. F. de Fonseca et al., “Alterations in cytokines and haematological parameters during the acute and convalescent phases of Plasmodium falciparum and Plasmodium vivax infections,” Memorias do Instituto Oswaldo Cruz, vol. 109, no. 2, pp. 154–162, 2014.

[32] C. G. Reiley and O. Barrett Jr., “Leukocyte response in acute malaria,” The American Journal of the Medical Sciences, vol. 262, no. 3, pp. 153–158, 1971.
33] B. Eriksson, U. Hellgren, and L. Rombo, "Changes in erythrocyte sedimentation rate, C-reactive protein and hematological parameters in patients with acute malaria," *Scandinavian Journal of Infectious Diseases*, vol. 21, no. 4, pp. 435–441, 1989.

34] U. M. Jadhav, R. Singhvi, and R. Shah, "Prognostic implications of white cell differential count and white cell morphology in Malaria," *Journal of Postgraduate Medicine*, vol. 49, no. 3, pp. 218–220, 2003.

35] L. H. Camacho, P. Wilairatana, G. Weis et al., "The eosinophilic response and haematological recovery after treatment for *Plasmodium falciparum* malaria," *Tropical Medicine and International Health*, vol. 4, no. 7, pp. 471–475, 1999.

36] E. Goldstein, "A clinical study of falciparum and vivax malaria in Vietnam servicemen," *Military Medicine*, vol. 133, no. 12, pp. 991–996, 1968.

37] A. Rasheed, S. Saeed, and S. A. Khan, "Clinical and laboratory findings in acute malaria caused by various plasmodium species," *Journal of the Pakistan Medical Association*, vol. 59, no. 4, pp. 220–223, 2009.

38] L. W. P. Church, T. P. Le, J. P. Bryan et al., "Clinical manifestations of *Plasmodium falciparum* malaria experimentally induced by mosquito challenge," *Journal of Infectious Diseases*, vol. 175, no. 4, pp. 915–920, 1997.

39] M. W. Richards, R. H. Behrens, and J. E. Doherty, "Short report: hematologic changes in acute, imported *Plasmodium falciparum* malaria," *The American Journal of Tropical Medicine and Hygiene*, vol. 59, no. 6, p. 859, 1998.

40] L. Schofield, L. Vivas, F. Hackett, P. Gerold, R. T. Schwartz, and S. Tachado, "Neutralizing monoclonal antibodies to glycosylphosphatidylinositol, the dominant TNF-α-inducing toxin of *Plasmodium falciparum*: prospects for the immunotherapy of severe malaria," *Annals of Tropical Medicine and Parasitology*, vol. 87, no. 6, pp. 617–626, 1993.

41] A. R. Miller, J. Suttles, and R. D. Stout, "Cytokine priming reduces dependence on TNF-R2 for TNF-α-mediated induction of macrophage nitric oxide generation," *Journal of Interferon and Cytokine Research*, vol. 16, no. 12, pp. 1055–1063, 1996.

42] H. H. Simms, T. A. Gaither, L. F. Fries, and M. M. Frank, "Monokines released during short-term FCγ receptor phagocytosis up-regulate polymorphonuclear leukocytes and monocyte-phagocytic function," *Journal of Immunology*, vol. 147, no. 1, pp. 265–272, 1991.

43] I. M. Elhassan, L. Hviid, G. Satti et al., "Evidence of endothelial inflammation, T cell activation, and T cell reallocation in uncomplicated *Plasmodium falciparum* malaria," *The American Journal of Tropical Medicine and Hygiene*, vol. 51, no. 3, pp. 372–379, 1994.

44] L. Hviid, J. A. L. Kurtzhals, B. Q. Goka, J. O. Oliver-Commey, F. K. Nkrumah, and T. G. Theander, "Rapid reemergence of T cells into peripheral circulation following treatment of severe and uncomplicated *Plasmodium falciparum* malaria," *Infection and Immunity*, vol. 65, no. 10, pp. 4090–4093, 1997.

45] J. Matsumoto, S. Kawai, K. Terao et al., "Malaria infection induces rapid elevation of the soluble Fas ligand level in serum and subsequent T lymphocytopenia: possible factors responsible for the differences in susceptibility of two species of Macaca monkeys to *Plasmodium coatneyi* infection," *Infection and Immunity*, vol. 68, no. 3, pp. 1183–1188, 2000.

46] P. Kern, M. Dietrich, C. Hemmer, and N. Wellinghausen, "Increased levels of soluble Fas ligand in serum in *Plasmodium falciparum* malaria," *Infection and Immunity*, vol. 68, no. 5, pp. 3061–3063, 2000.

47] L. Hviid, K. Kemp, P. Kern et al., "What is the cause of lymphopenia in malaria?" *Infection and Immunity*, vol. 68, no. 10, pp. 6087–6089, 2000.

48] J. A. L. Kurtzhals, C. M. Reimert, E. Tette et al., "Increased eosinophil activity in acute *Plasmodium falciparum* infection—association with cerebral malaria," *Clinical & Experimental Immunology*, vol. 112, no. 2, pp. 303–307, 1998.

49] Q. de Mast, E. Groot, P. J. Lenting et al., "Thrombocytopenia and release of activated von Willebrand factor during early *Plasmodium falciparum* malaria," *Journal of Infectious Diseases*, vol. 196, no. 4, pp. 622–628, 2007.

50] N. Karunaweera, D. Wanasekara, V. Chandrasekharan, K. Mendis, and R. Carter, "Plasmodium vivax: paroxysm-associated lipids mediate leukocyte aggregation," *Malaria Journal*, vol. 6, article 62, 2007.